89bio News

89bio to Participate in the BofA Securities 2024 Health Care Conference

SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver

GlobeNewswire04:05

All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy

Yahoo FinanceMay 7 00:00

89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH

PDF Version Webinar to feature a presentation from expert hepatologist Arun Sanyal, M.D., on Thursday, May 16th at 10am ETSAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ET

89bioMay 2 12:00

89bio Coverage Assumed by B of A Securities at Buy

89bio Coverage Assumed by B of A Securities at Buy

Dow JonesApr 22 18:24

B of A Securities Assumes 89bio at Buy, Announces Price Target of $30

B of A Securities analyst Alexandria Hammond assumes 89bio (NASDAQ:ETNB) with a Buy rating and announces Price Target of $30.

BenzingaApr 22 18:14

Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints

Seeking AlphaApr 20 05:10

89bio Enhances Board With Biopharma Veteran Martin Babler

TipRanksApr 18 04:22

89bio Appoints Biotech Industry Veteran, Martin Babler to Its Board of Directors

89bio, Inc. (Nasdaq: ETNB) today announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024.

GlobeNewswireApr 18 04:05

89bio Signs Deal for Construction of a Production Facility in China

Seeking AlphaApr 11 05:14

On April 4, 2024, 89Bio Entered Into Collaboration Agreement With BiBo Biopharma Engineering - Filing

BiBo will construct a production facility specifically designed to supply the Company with pegozafermin for commercialization, if approved. Under the Collaboration Agreement, the Company will pay BiBo

BenzingaApr 11 04:35

Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra

Seeking AlphaApr 9 22:03

89bio Price Target Maintained With a $29.00/Share by Cantor Fitzgerald

89bio Price Target Maintained With a $29.00/Share by Cantor Fitzgerald

Dow JonesApr 5 21:33

Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target

Cantor Fitzgerald analyst Kristen Kluska reiterates 89bio with a Overweight and maintains $29 price target.

Analyst UpgradesApr 5 21:23

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PDF Version SAN FRANCISCO, April 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and co

89bioApr 5 12:00

89bio Inc CEO Rohan Palekar Sells 52,718 Shares

Yahoo FinanceApr 4 07:01

89bio(ETNB.US) Officer Sells US$575.15K in Common Stock

$89bio(ETNB.US)$ Officer PALEKAR ROHAN sold 52,718 shares of Common Stock on Apr 1, 2024 at an average price of $10.91 for a total value of $575.15K.Source: Announcement What is statement of changes i

Futu NewsApr 4 04:41

89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing

Rohan Palekar, Director, Chief Executive Officer, on April 01, 2024, sold 52,718 shares in 89bio (ETNB) for $575,153. Following the Form 4 filing with the SEC, Palekar has control over a total of 459,

MT NewswiresApr 4 04:07

Form 144 | 89bio(ETNB.US) Officer Proposes to Sell 574.93K in Common Stocks

SEC FILLINGS DISCLOSED/ Apr 1, $89bio(ETNB.US)$ Officer ROHAN PALEKAR intends to sell 52,718 shares of its common stock on Apr 1, with a total market value of approximately $574.93K. ROHAN PALEKAR h

Futu NewsApr 2 07:33

Buy Rating Affirmed for 89bio's Pegozafermin: A Promising NASH Treatment With Strong Regulatory Endorsements

TipRanksMar 29 15:09

HC Wainwright & Co. Maintains Buy on 89bio, Maintains $31 Price Target

HC Wainwright & Co. analyst Ed Arce maintains 89bio with a Buy and maintains $31 price target.

Analyst UpgradesMar 28 01:53